# Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer

> **NCT06653972** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Wang Jiayu** · enrollment: 30 (estimated)

## Conditions studied

- Her2-negative Metastatic Breast Cancer
- Vinorelbine
- Liposomal Doxorubicin

## Interventions

- **DRUG:** Pegylated Liposomal Doxorubicin + vinorelbine,every cycle is 14d.

## Key facts

- **NCT ID:** NCT06653972
- **Lead sponsor:** Wang Jiayu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2026-02-01
- **Final completion:** 2026-09-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06653972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06653972, "Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06653972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*